Lineage Cell Therapeutics, Inc. (LCTX) |
1.66 -0.09 (-5.14%) 10-10 16:00 |
Open: | 1.75 |
High: | 1.78 |
Low: | 1.63 |
Volume: | 2,341,954 |
Market Cap: | 379(M) |
PE Ratio: | -9.76 |
Exchange: | New York Stock Exchange Arca |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 2.14 |
Resistance 1: | 1.83 |
Pivot price: | 1.68 |
Support 1: | 1.44 |
Support 2: | 1.20 |
52w High: | 1.83 |
52w Low: | 0.37 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
EPS | -0.170 |
Book Value | 0.210 |
PEG Ratio | 0.00 |
Gross Profit | -0.010 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -178.66 |
Return on Assets (ttm) | -13.2 |
Return on Equity (ttm) | -71.5 |
Tue, 30 Sep 2025
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Up 4.7% - Should You Buy? - MarketBeat
Tue, 23 Sep 2025
Baird reiterates Outperform rating on Lineage Cell stock after Roche R&D Day - Investing.com
Tue, 23 Sep 2025
Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial - Yahoo Finance
Tue, 02 Sep 2025
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences - Business Wire
Sun, 31 Aug 2025
Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Wed, 13 Aug 2025
Lineage Cell Therapeutics Inc (LCTX) Q2 2025 Earnings Call Highlights: Strategic Partnerships ... - Yahoo Finance
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |